Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rosetta Genomics Ltd ROSGQ

Healthcare Biotechnology Diagnostics & Research
Rosetta Genomics Ltd. is an Israel-based company engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA), and protein biomarkers, and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence... see more

Recent & Breaking News (GREY:ROSGQ)

Rosetta Genomics Reports 2017 Second Quarter and Six Months Financial Results

Accesswire October 10, 2017

Rosetta Genomics Announces $2 Million Private Placement

Accesswire September 28, 2017

Rosetta Genomics Enters into Agreement to Sell Its PersonalizeDx Business to Pragmin Prognosis

Accesswire September 8, 2017

Rosetta Genomics Expands Global Patent Protection for RosettaGX Reveal with Patent Allowance in Japan

Accesswire September 6, 2017

Rosetta Genomics to Reduce Operating and Other Expenses

Accesswire September 5, 2017

Major Clinical Reference Laboratory Selects RosettaGX Reveal Thyroid miRNA Classifier as Molecular Test of Choice

Accesswire August 21, 2017

Rosetta Genomics Announces Pricing of $2.73 Million Financing

Accesswire August 4, 2017

Clinical Utility Survey Demonstrates the Potential of RosettaGX Reveal(TM) to Significantly Reduce Unnecessary Thyroid Surgeries

Accesswire July 31, 2017

RosettaGX Reveal(TM) to be Highlighted in Oral Presentation at the 3rd World Congress on Thyroid Cancer

Accesswire July 26, 2017

Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China

Accesswire July 6, 2017

Rosetta Genomics Granted European Patent Allowance Covering RosettaGX Cancer Origin Assay

Accesswire May 25, 2017

Rosetta Genomics Enters Collaboration to Develop a microRNA Classifier Relating to Patients with Non-Small Cell Lung Cancer Considered for Treatment with Immuno-oncology Drugs

Accesswire May 23, 2017

Rosetta Genomics Focusing Efforts on Improving Cash Position through Sale of the PersonalizeDx Business and Monetizing IP

Accesswire May 22, 2017

Rosetta Genomics Announces Favorable Results from Two Pilot Studies Comparing RosettaGX Reveal(TM) and the Afirma GEC Assay for the Classification of Indeterminate Thyroid Nodules

Accesswire May 12, 2017

Rosetta Genomics Expands International Access for RosettaGX Reveal(TM) through Agreement with Cytolog Laboratories in Brazil

Accesswire May 5, 2017

Rosetta Genomics Receives Final Approval from New York State for First-of-its-kind Thyroid Cancer Diagnostic Assay

Accesswire May 4, 2017

Rosetta Genomics to Increase Investment in RosettaGX Reveal(TM) and Explore Strategic Alternatives for the PersonalizeDx Business

Accesswire May 2, 2017

Rosetta Genomics Expands Patent Portfolio in Europe and Japan

Accesswire May 1, 2017

New Data Highlighting the Powerful Performance of RosettaGX Reveal(TM) in Identifying Medullary Thyroid Cancer to be Presented at the AACE 2017 Annual Meeting

Accesswire April 27, 2017

Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results

Accesswire March 30, 2017